Catalent Pharma Solutions today announced Catalent Biologics will adopt BLI’s Beacon® optofluidic platform to accelerate its cell line development workflow.
SOMERSET, N.J. – July 10, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Berkeley Lights, Inc. (BLI), a leader in digital cell biology, today announced Catalent Biologics will adopt BLI’s Beacon® optofluidic platform to accelerate its cell line development workflow.
The Beacon platform is capable of screening thousands of clones in parallel. In just five days, the top producing clones are identified and scale up can begin, expediting the development process. Automating the process on the Beacon platform increases efficiencies, allows for faster identification of the top producing clones and provides additional insights into the behavior of clonal populations that are currently unavailable using traditional techniques. The four integrated workflows of the Beacon platform – import, culture, assay, and export, will be applied to Catalent Biologics’ GPEx® cell line development platform, as well as Catalent’s ongoing research and development activities.
“Catalent has a history of applying advanced technologies to provide a differentiated offering to our customers,” said Mike Riley, Vice President and General Manager of Drug Substance and Bioanalytical services for Catalent Biologics. He added, “Implementing the Beacon platform for cell line development has the potential to significantly accelerate our customers’ development timelines and bring more transformational biologic therapeutics to patients.”
“We are delighted to be working with Catalent and share their vision of speeding timelines and increasing efficiencies for customers,” said Andy Last, Chief Commercial Officer at Berkeley Lights, Inc. “The value that the Beacon platform creates for the biopharmaceutical market can be seen with its rapid adoption. Today, approximately 50% of the top 25 biopharmaceutical companies have implemented the Beacon platform for one or more workflows, and we’re excited that Catalent Biologics is the first technology and service provider to launch the platform in North America.”
To learn more about the Beacon Cell Line Development (CLD) Workflow, visit https://www.berkeleylights.com/beacon-applications/cell-line-development.
+44 (0)7580 041073
+44 (0) 161 728 5880
About Catalent Biologics
Catalent Biologics provides advanced technologies and tailored solutions for biologic and biosimilar development, from DNA to commercial supply, through our extensive Biologics network including: Madison, Wisconsin; Emeryville, California; Kansas City, Missouri; Morrisville, North Carolina and Bloomington, Indiana. For more information on Catalent Biologics, visit catalentbiologics.com.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
About Berkeley Lights
Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell based products and therapies.
At the intersection of biology, technology and information, our platforms automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. The Beacon platform* is ideally suited for cell line development, antibody discovery (including direct B-cell workflows), gene editing, and antibody engineering workflows. Each workflow provides a 100 fold increase in insights, 10 times faster, at a fraction of the cost. * For Research Use Only. Not for use in diagnostic procedures.
For more information, visit berkeleylights.com.